Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma

Neuro-Oncology

Volumn 12, Issue 7, 2010, Pages 720-724

  Pels, Hendrik ^a   Juergens, Annika ^a   Schirgens, Isabell ^b   Glasmacher, Axel ^b   Schulz, Holger ^c   Engert, Andreas ^c   Schackert, Gabriele ^d   Reichmann, Heinz ^d   Kroschinsky, Frank ^d   Vogt Schaden, Marlies ^e   Egerer, Gerlinde ^e   Bode, Udo ^b   Deckert, Martina ^c   Fimmers, Rolf ^b   Urbach, Horst ^b   Schmidt Wolf, Ingo G H ^b   Schlegel, Uwe ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Primary CNS lymphoma; Prognosis

Indexed keywords

CYTARABINE; DEXAMETHASONE; METHOTREXATE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTRAST ENHANCEMENT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; TREATMENT RESPONSE; TUMOR REGRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650258873     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq010     Document Type: Article

References (19)

1. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol. 1999;26:346-356.
2. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18: 3144-3150.
3. Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatmentmodality. Int J Radiat Oncol Biol Phys. 1998;41:615-620.
4. McAllister LD. Primary central nervous system lymphoma: a review. Curr Neurol Neurosci Rep. 2002;2:210-215.
5. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266-272.
6. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711-5715.
7. Yu HJ, Chen JH, Mehta RS, Nalcioglu O, Su MY. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging. 2007;26: 615-623.
8. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat. 2003;78:51-58.
9. MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging. 2007;7:10-18.
10. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523.
11. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489-4495. (Pubitemid 46594018)
12. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043.
13. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer LymphomaGroup Phase IITrial 20962. J Clin Oncol .2003;21:4483-4488.
14. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16:859-863.
15. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865-3870.
16. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26:2512-2518.
17. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730-4735.
18. Cha S. CNS tumors: monitoring therapeutic response and outcome prediction. Top Magn Reson Imaging. 2006;17:63-68.
19. Holscher HC, Bloem JL, van der Woude HJ, et al. Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy? Clin Radiol. 1995;50:384-390.